Kancera: Underestimated optionality

Coverage Initiation

2024-05-22

06:50

Redeye initiates coverage of Kancera, a Swedish life science company developing candidates targeting myocardial infarction and ovarian cancer. As clinical studies indicate a widely applicable treatment mechanism, we believe the stock market currently underestimates the upside optionality in the case.

Martin Wahlström

Kevin Sule

Analyst Q&A

Closed

Martin Wahlström answered 3 questions.

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.